Disclosures: Moreau reports being an employee of L’Oréal.
December 27, 2021
1 min read
Save

S. aureus-based product improves outcomes in pediatric, adult atopic dermatitis

Disclosures: Moreau reports being an employee of L’Oréal.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Both children and adults with atopic dermatitis showed disease improvement with minimal adverse outcomes after using a Staphylococcus aureus-based topical treatment, according to a study.

“The efficacy and tolerance of a cream containing a S. aureus-targeting technology (endolysin) was assessed in an open-label, 2-week study in children and adults with mild to moderate atopic dermatitis,” Magali Moreau, PhD, of L’Oréal Recherche & Innovation, and colleagues wrote.

The 43 study participants were aged 7 months to 57 years. The researchers assessed disease severity using the SCORing Atopic Dermatitis (SCORAD) system at days 0, 7 and 14. In addition, patients completed the Patient-Oriented SCORAD (PO-SCORAD) questionnaire to assess pruritus, tingling and burning on days 0, 3, 7 and 14. The Dermatology Life Quality Index and Children’s Dermatology Life Quality Index questionnaires also were used on those same days.

Participants used the study drug topically two or three times daily throughout the study duration.

Results showed a 43% reduction in overall SCORAD score at 7 days and 68% by 14 days.

A statistically significant decrease in PO-SCORAD was reported as early as day 3 of follow-up. Moreover, this score decreased by an average of 30% at day 7 and 50% by day 14. All participants reported improvement at the 2-week mark.

Looking closer at 14-day efficacy outcomes, itching decreased by 51%, while tingling decreased by 63% and burning decreased by 79% (P < .005 vs. baseline).

QOL outcomes showed that 100% of pediatric patients and 95% of adults improved by these parameters by day 14.

No adverse events were reported by anyone in the cohort. Cutaneous discomfort, redness, small pimples or dryness were reported by nine patients. However, these events were deemed to be associated with AD and not the study drug.

“This study shows the efficacy of a highly specific S. aureus-targeted technology in alleviating symptoms and improving QOL in children and adults with atopic dermatitis,” the researchers concluded. “It could also be beneficial in reducing and preventing flares in subjects with S. aureus load due to its good tolerance and specific action.”